Open AccessFollistatin Like 5 (FSTL5) inhibits epithelial to mesenchymal transition in hepatocellular carcinoma
Author(s) -
DengYong Zhang,
Jiasheng Lei,
Weili Sun,
Dongdong Wang,
Zheng Lu
Publication year - 2020
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000000847
Subject(s) - vimentin , follistatin , epithelial–mesenchymal transition , hepatocellular carcinoma , immunohistochemistry , metastasis , cancer research , western blot , medicine , pathology , cancer , oncology , biology , gene , biochemistry
Epithelial to mesenchymal transition (EMT) is a key process in determining distant metastasis and intra-hepatic dissemination of hepatocellular carcinoma (HCC). Follistatin (FST) family members are considered to be an attractive therapeutic targets and prognostic indicators in cancers. As a derivative of FST, Follistatin Like 5 (FSTL5) may play a similar role in HCC cells. This study aimed to investigate the expression and function of FSTL5 in HCC and its role in EMT.